LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Journal Article > Letter

TB research requires strong protections, innovation, and increased funding in response to COVID-19

Nyang'wa BT, LaHood AN, Mitnick CD, Guglielmetti L
Download
Download
Abstract
When 2020 opened, approximately 11 million new tuberculosis (TB) cases and nearly 1.5 million TB-related deaths were predicted during the year. And, the gap between required and available research and development resources for TB was estimated at more than 1 billion USD. COVID-19, the global pandemic of disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has surely widened that gap by worsening the TB pandemic. Worryingly, the economic devastation wrought by COVID-19 portends further dramatic reductions in funds for other health research, including for multidrug-resistant tuberculosis (MDR-TB). Such constraints will prevent the use of extant TB research infrastructure to support cross-disease benefits in the struggle against COVID-19 and future pandemics.
Subject Area
tuberculosisCovid-19
Collections
TB-PRACTECAL Trial—Evidence for a shorter, safer, more effective treatment for drug-resistant tuberculosis
DOI
10.1186/s13063-021-05331-4
Published Date
29-May-2021
PubMed ID
34051826
Languages
English
Journal
Trials
Volume / Issue / Pages
Volume 22, Issue 1, Pages 371
Dimensions Badge